All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
At the 60th American Society of Hematology (ASH) Annual Meeting, Andreas Burchert from the University of Marburg, Germany, discusses the study findings of the Sormain trial, which is evaluating sorafenib as maintenance therapy after allogeneic stem cell transplantation for patients with FLT3-ITD–positive acute myeloid leukemia.
Andreas Burchert | ASH 2018 | Key highlights of the Sormain trial
Editorial theme │ Maintenance therapy for AML
Maintenance therapy has been proven very efficacious at improving long-term patient outcomes and reducing relapse in the acute lymphoblastic leukemia (ALL) setting. Thus, research into the role of...
ASH 2018 | Maintenance therapy with sorafenib in patients with FLT3-ITD acute myeloid leukemia – SORMAIN trial
SORMAIN trial demonstrates for the first time, evidence that FLT3 inhibition after allo-SCT is feasible and significantly reduces the risk...
Subscribe to get the best content related to AML delivered to your inbox